Translate
Ligand Pharmaceuticals Incorporated
About
217.75USD+9.97 +4.80%
Closed • Updated at 13:10 GMT+00:00Market Cap$4.36B
P/E Ratio29.52
Volume260.3K
Beta0.85
RSI49.09
Gross Margin83.42%
Ligand Pharmaceuticals Incorporated — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Ligand Reports First Quarter 2026 Financial Results
May 6 2026
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Apr 27 2026
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Apr 22 2026
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Apr 14 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS